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Abstract
The use of Doppler techniques, including power, colour and spectral Doppler, has greatly increased in
rheumatology in recent years. This is due to the ability of Doppler US (DUS) to detect pathological vas-
cularization within joints and periarticular soft tissues, thereby demonstrating the presence of active in-
flammation, which has been reported to be correlated with the local neo-angiogenesis. In synovitis, DUS
showed a high correlation with histological and MRI findings, thus it is considered a valid tool to detect
pathological synovial vascularization. Moreover, it is more sensitive than clinical examination in detecting
active joint inflammation and in the evaluation of response to treatment. In addition, DUS may be
considered as a reference imaging modality in the assessment of enthesitis, MRI being not sensitive
and histology not feasible. Moreover, it has been demonstrated to be able to detect changes in asymp-
tomatic enthesis. In conclusion, DUS is a useful and sensitive tool in the evaluation and monitoring of
active inflammation. Its widespread use in clinical rheumatological practice is recommended. The aim of
this article is to review the current literature about the role of DUS in rheumatic diseases, analysing its
validity, reliability and feasibility.
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Introduction
The growing role of US in rheumatology
In the last decade, the employment of US in rheumatic
diseases has greatly increased, with improvement and
widespread diffusion of US machines and an increasing
number of rheumatologists who are able to perform
musculoskeletal US. Considering the capacity of US to
image several anatomical structures and its higher sensi-
tivity in the detection of joint and periarticular soft tissue
abnormalities compared with physical examination, US
has now been integrated in daily clinical practice and its
fields of application are increasing [1]. Doppler modalities
are currently considered an integral part of the global
sonographic assessment of the rheumatic patient. This
is mainly due to their capability to detect pathological
flow within musculoskeletal soft tissues, thereby demon-
strating the presence of local active inflammation [2].
Doppler modalities: colour Doppler,
power Doppler and spectral Doppler
Three modalities of Doppler US (DUS) are currently used
in the assessment of rheumatic diseases (Table 1). Colour
Doppler (CD) US is obtained by the mean Doppler shift of
the moving red cells, so it shows the direction and the
speed of flow, without giving any information about the
number of moving cells. No flow is detected if a vessel
is perpendicular to the US beam [3, 4]. Power Doppler
(PD) US, instead, evaluates the total number of Doppler
shifts of the moving cell, regardless of direction and
speed, thereby detecting flow also in case of perpendicu-
larity of the flow to the US beam, and hence is a very
sensitive tool for detecting slow flows [3, 4]. Spectral
Doppler (SD) US provides an analysis of the flow in a se-
lected vascularized site (i.e. a single vessel), giving infor-
mation about its speed and direction and analysing them
in a time-integrated image that allows the differentiation of
the single components of the flow (systole and diastole).
As the musculoskeletal structures are characterized by
high-resistance flows, the resistance index (RI), which is
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the ratio between the systolic peak minus the end diastol-
ic flow and the systolic peak, has a value of 1 in normal
conditions; a decrease in the RI is registered in case of
inflammation or neo-angiogenesis [5].
The role of DUS in the assessment of
synovitis
Doppler vs MRI and histopathology
In the whole of the literature, there are few works compar-
ing synovial DUS with histopathological findings and the
majority of them concerns large joints, before prosthetic
substitution. The first study comparing DUS with histology
was done to perform a differential diagnosis on IA echoic
structures in 10 patients with RA and 10 with OA before
prosthetic replacement. In nine patients, histology
showed a vascularized pannus and DUS demonstrated
synovial vascularization. No significant differences were
demonstrated between the use of PD and CD, thereby
suggesting a similar role of PD and CD in improving the
differentiation of IA structures [6].
In 2001, Walther et al. [8] compared PD and synovial
histopathology of the knee joint in 23 patients (10 affected
by RA, 13 by OA) who were undergoing total knee arthro-
plasty. They evaluated both grey-scale and PD synovitis,
quantifying them on a 4-point scale, according to the
Newman score [7], and adding an automatic quantification
of red pixels as sign of vascularization. Both the qualitative
and the quantitative estimation of vascularization corre-
lated with the histopathological findings, leading to the
conclusion that PD is a valid tool for the detection and
quantification of synovial vascularization [8]. One year
later, a similar work was done on the hip using the same
protocol (24 patients, 15 with OA and 9 with RA); the
results showed a good correlation between histological
findings and PD in the detection of synovial vascularity [9].
The difference in equipment capacity to determine very
slow flows and the correlation of PD with histopathology
was tested in 44 synovial sites (25 knees, 7 wrists, 3 tibio-
talar joints, 2 MTP joints, 1 glenohumeral, 1 MCP, 1 elbow,
2 subdeltoid bursae and 2 tendon sheaths). A difference in
the lowest detectable flow was found testing the ma-
chines on phantoms. In 83% of patients who showed
histological signs of active synovial inflammation, a posi-
tivity of PD was detected without any correlation between
the amount of PD signal and the overall histopathological
score, but with a good correlation between the amount of
sub-synovial infiltration of PMNs and the amount of
surface fibrin. The authors concluded that a negative PD
flow cannot exclude an active synovitis, whereas a posi-
tive one is a good indicator of it, regardless of its
degree [10].
When contrast-enhanced MRI (CE-MRI) has been used
for assessing the validity of PD, a good correlation
between the two techniques has been shown. Indeed, in
a study performed in 54 MCP joints of RA patients,
a positive PD signal was demonstrated in 17 joints and
CE-MRI showed increased flow in 18 joints; in this study,
the sensitivity of PD was 88.8% and the specificity was
97.9% [11].
Terslev et al. [12] evaluated the qualitative and quanti-
tative CD signal, the RI and the CE-MRI data in a larger
number of joints (29 wrist and 167 finger joints). There
was a significant correlation between MRI post-contrast
synovial thickness, Doppler colour fraction and RI.
Vascularized synovial membrane was found also in
some asymptomatic joints, thus demonstrating a high
sensitivity of CD [12]. In 2007, a comparison between
PD, MRI and radiography (X-ray) was done in the hands
and feet of 15 PsA patients, 5 RA patients and 5 controls;
the data showed a good correlation between PD and MRI
in depicting bone changes and synovitis both in RA and
PsA [13].
Few papers have evaluated the validity and reliability of
PDUS to detect synovitis in the shoulder of patients with
RA. In the first one, comparing PDUS before and after
administration of echo-enhancing contrast agent with
CE-MRI in 24 RA patients’ shoulders, less encouraging
results were found [14]. Indeed, US detected synovial
effusion/hypertrophy in 42% of the patients showing
synovitis with CE-MRI, whereas a positive PD signal was
not found in any of them, leading the authors to the con-
clusion that PD is not a valid tool to assess the synovial
activity in this joint [14].
However, these findings are not in agreement with
those obtained later by two studies that compared
grey-scale US and PD with MRI in a small number of
RA patients, evaluating also the inter-observer reliability,
and found that PDUS was reliable and is a valid tool
for the assessment of shoulder synovitis in RA [15, 16].
These apparent contradictory results can be explained
by the different US definitions of synovitis, the differ-
ent cut-off values for pathological findings and the
different MRI protocols, including the variable use of
contrast.
TABLE 1 Characteristics of Doppler modalities used in
rheumatology
CD
Combines Doppler effect and real-time imaging
Assesses the mean velocity of blood flow overlapping
colour and B-mode images
A colour signal is displayed—different colour according
to the direction of flow (red: the flow directs towards
the probe; blue: away from it)
PD
Displays the power of Doppler signal in a large range
of Doppler shifts
Small flow is detected (but NOT its direction and
velocity)
The capability to highlight flow depends on the quality
of the US equipment
Is a mainstay in assessing inflammation in joints and
periarticular tissues in rheumatic diseases
SD
Provides an analysis of the flow in a selected
vascularized site
The RI decreases in case of synovial inflammation
www.rheumatology.oxfordjournals.org 977
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Doppler vs clinical assessment and its role in the
assessment of disease progression and response to
therapy
Doppler vs clinical assessment
In 2007, a comparison of PD and traditional clinical as-
sessment of joints in RA patients did not show significant
correlations between clinically detected (tenderness,
swelling or none of these) and PD-detected synovitis.
Indeed, synovitis was also found in some asymptomatic
patients, raising the question about the role of the
traditional clinical assessment of joints in RA [17].
Despite clinical remission, radiological damage pro-
gression can be found in RA patients; this led to the evalu-
ation of 107 RA patients, asymptomatic for joint pain and
in remission according to DAS-28 and ACR criteria, with
MRI and PD. Synovitis was found in the majority of these
patients, both with MRI and PD, giving a possible explan-
ation for the radiological progression and confirming the
importance of sonography in the management of RA [18].
Later on, a longitudinal study evaluated 102 patients in
clinical remission with PD and MRI at baseline and after
12 months, finding a significant correlation between the
baseline synovitis and the further occurrence of radio-
logical damage; a relevant finding seemed to be the de-
tection of a PD signal, which was associated with a very
increased risk of developing bone erosions (odds ratio
12.21) [19].
The role of Doppler in therapy monitoring
In 2003, a pilot study was conducted to depict the role of
PD in the follow-up of RA patients treated with infliximab;
a small number of patients were enrolled, and the sono-
graphic analysis was performed at the level of small joints.
A good correlation between the clinical response to ther-
apy and the decrease in synovial thickness and the PD
signal was found, demonstrating that PD is a feasible and
sensitive tool to measure the response to therapy in RA
[20].
The role of PD in monitoring the response to therapy
was confirmed the same year in 13 RA patients treated
with i.v. methylprednisolone [21]. In 2004, Taylor et al. [22]
compared the results obtained in RA patients treated with
MTX + infliximab vs MTX + placebo, evaluating them with
PD at Weeks 0, 2, 6 and every 8 weeks until Week 46.
A difference in the response rate in the two groups and
a correlation between the baseline PD US condition and
the radiological progression at Week 54 were found [22].
Similar results were obtained 2 years later with the
same drug, confirming the importance of PD in monitoring
therapy response [23]. After this, DUS was applied on
knee synovitis both in RA and in PsA to evaluate the re-
sponse to etanercept; a decrease in synovial vasculariza-
tion was detected in the responder patients, and this
correlated with the improvement of clinical assessment
and biohumoral markers, without any significant differ-
ence between PsA and RA [24].
In 2006, treatment with adalimumab was monitored for
2 weeks with PD that demonstrated a rapid decrease in
synovial pathological flow after treatment [25]. In 2008, the
same authors confirmed the results in a follow-up period
of 2 years [26]. In the same year, sensitivity to change in
PDUS in 28 joints of RA patients on anti-TNF therapy was
demonstrated in a larger cohort, showing a correlation
with the improvement in DAS-28 and a predictive value
for radiological progression [27].
The ability in detecting short-time modifications was
also evaluated in 20 patients with PD-proven active syno-
vitis treated with IA steroid injections; 2 weeks after a
steroid injection a decrease in pathological vascularity
and synovial thickening were found [28].
For the follow-up of RA patients, both the extensive
PDUS evaluation of 44 joints and the reduced evaluation
of 12 joints have shown to be sensitive to change and
to correlate with the composite indexes of disease activ-
ity; however, the reduced count results have been found
to be more feasible [29].
Later on, a 78-joint PDUS count also demonstrated a
correlation with the modifications of the clinical and
biohumoral parameters during therapy with adalimumab
in a follow-up of 12 months [30]. In 2010, a prospective
study showed not only the usefulness of PD in monitoring
infliximab therapy, but also demonstrated the possibility
of detecting a decrease in Doppler signal as early as Week
2 and established Week 38 as the best time to perform
follow-up in order to predict the successive response
to therapy [31].
Predictive value of Doppler
Ozgocmen et al. [32] compared the sonographic assess-
ment of inflammation in MCP joints of RA patients (eval-
uated with grey scale, PD and SD) with the articular BMD.
The results demonstrated a significant correlation be-
tween PD and erosive scores and an inverse correlation
between RI and BMD and erosive scores; these results
therefore seem suggestive of a possible role of flow meas-
urement techniques in RA follow-up. The role of PD signal
at baseline as a predictive index for erosion [33] and for
short-term relapse [34] was then confirmed by other
research studies, not only in RA but also in JIA [35].
In 2007, 42 patients with early RA underwent PDUS
assessment of 28 joints at baseline, 3 months, 6 months
and 1 year and radiographic assessment at baseline and
1 year. The US joint count for active synovitis and an over-
all joint index for power Doppler signal correlated with
radiographic progression, leading to the conclusion that
PDUS findings may have a predictive value in disease
activity and radiographic outcome [36].
The association of PD vascularization in a single MCP or
PIP joint, where inflammation was then confirmed by MRI,
with radiological progression has been evaluated in 19 RA
patients (190 MCP joints and 190 PIP joints). The pres-
ence of pathological vascularization (Fig. 1A) in a single
joint at baseline was associated with the radiographic
onset of erosions after 20 weeks of therapy, whereas a
decrease of vascularity was not associated with X-ray dis-
ease progression after 8 weeks of treatment [37].
These data were in agreement with another study about
a 2-year follow-up of RA patients, showing that the degree
of synovial hyperaemia at baseline and the number of
978 www.rheumatology.oxfordjournals.org
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ACR criteria were the only predictive factors for the
development of erosions [38]. More recently, a study
applying MRI, PDUS, CT scan and radiography on 52
RA patients on therapy with adalimumab and MTX
demonstrated the lack of clear evidence that subclinical
synovitis is responsible for radiological progression;
however, PDUS-detected synovitis as well as bone
oedema at baseline have been found to be risk factors
for erosions [39].
The role of DUS in enthesitis
Doppler vs clinical assessment and its role in the
assessment of disease progression and response to
therapy
In 2003, D’Agostino et al. [40] evaluated 164 SpA patients
and 64 controls (34 with mechanical low back pain and
30 with RA), with particular attention towards lower limb
entheses vascularization at the cortical bone insertion,
junction between the tendon and enthesis, body of the
tendon and bursa. The majority of SpA patients showed
at least one US-detected abnormality at entheseal level on
grey scale or PD, compared with only a few patients with
RA or mechanical low back pain. A high number of SpA
patients showed abnormal enthesis vascularization, and
the most remarkable point was the site of PD positivity:
the cortical bone insertion showed flow in almost all the
patients, whereas none of the RA patients and mechanical
low back pain patient had flow in that area (Fig. 1B). The
vascularization also correlated with the clinical presenta-
tion, with a more sustained vascularization in the mixed
form than in the axial one [40].
Later on, a comparison between PD evaluation of 390
entheses (30 AS patients) and the Modified American
Shoulder and Elbow Surgeons (MASES) score [41]
obtained by palpation and algometric pain threshold
was done, together with the collection of biohumoral
parameters. The sonographic evaluation was carried out,
registering both grey-scale and PD abnormalities by a
semiquantitative (03) grading system. A cumulative PD
score was then calculated for each patient by summing
the scores of any single enthesis. A positive correlation
was found between the cumulative PD score and
MASES score, whereas no correlation was found between
these data and age, disease duration, morning stiffness
and anthropometric measures. Highly vascularized
entheses on PD were found to be a possible cause of
pain [42].
Recently, an attempt to standardize enthesitis by DUS
and improve inter- and intra-observer reliability has been
done by applying a multi-step process, which produced
an improvement in the reliability over the time [43] and has
been recently demonstrated to be a useful tool in moni-
toring therapy. After a short report about the use of PD to
monitor the effects of infliximab on enthesitis in two pa-
tients [44], in 2010 a larger series of 43 patients was
evaluated, with the results demonstrating a decrease in
vascularization detected by PD in the treated patients at
the entheseal level [45].
The same year, a study on a larger cohort of 327 SpA
patients with enthesitis confirmed that PDUS is sensi-
tive to change in assessing the response to anti-TNF-a
therapy [46].
Comparison of different Doppler
modalities
No study comparing PD and CD in rheumatic disease has
been performed so far. However, based on the apparent
increased sensitivity of PD in detecting slow flows over
CD, currently a wider application of it has been registered
and a greater number of studies on its uses are available.
However, it seems that the recent technical improvements
of US equipment have led to increased performances of
CD and to its widespread use [47]. Conversely, studies
comparing PD and CD with SD, in particular with the RI
and the pulsatility index, have been performed over the
last decade.
In 2001, an analysis on 18 inflamed joints in RA evalu-
ated the results obtained by clinical assessment, CD and
SD; a significant correlation between CD fraction and ESR
and between the RI with ESR and HAQ was found.
Interestingly, whereas an increase in vascularization at
CD was detected after injection of contrast medium, no
differences were seen with SD, indicating that contrast
enhancement is not necessary with this technique [48].
The response to treatment has been evaluated with dif-
ferent Doppler modalities. In 2003, 11 RA patients treated
with etanercept were assessed before and after the treat-
ment both with PD and with SD (RI): after the treatment, a
decrease in the PD score and an increase in the RI were
FIG. 1 Positive PD signal indicating active inflammation.
(A) Synovitis of the radiocarpal joint in an RA patient.
(B) Enthesitis of the tricipital tendon in a PsA patient.
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detected, showing that both methods can be useful in the
follow-up of RA patients [49]. Similar results were
obtained by the use of CD and SD after IA steroid injec-
tions [50].
That same year, results from qualitative/quantitative CD
assessment were correlated with MRI evaluation in 196
joints of RA patients. DUS was able to depict inflammation
in 52 joints, with significant differences between both CD
and RI and the degree of swelling, but with a correlation
of RI only with the degree of tenderness. The analysis
of CE-MRI showed the signs of local inflammation in
79 joints, as well as a global 75% of agreement with
DUS; in addition, a significant correlation between
post-contrast synovial thickness and both CD and RI
was found [12].
Conclusions
In recent years, DUS has gained increasing applications
and a relevant role in the assessment of inflammatory
arthritis, being now used also in the evaluation of disease
activity. Currently there are three DUS modalities that
seem to be appropriate for rheumatological applications:
PD, CD and SD. However, none of them has clearly been
demonstrated to be superior to the others.
PD, which is the most used DUS technique, has some
theoretical advantages over CD, mostly represented by its
supposed higher sensitivity in the detection of slow flows,
such as those present at the level of inflamed tissues.
In addition, it is able to show pathological vascularization
independently of the angle of insonation between the US
beam and the vessels, thus being more appropriate
for the analysis of neo-angiogenesis. However, due to
recent technological advances in new US equipment, it
seems that CD and PD have similar levels of sensitivity
in the detection of synovitis.
The use of spectral Doppler, in particular the evaluation
of RI, allows a quantification of the degree of vasodilation
of single vessels. At the joint level, the value of the RI is
usually 1 in healthy individuals; in case of inflammation
this parameter drops to <0.8 and can be applied to ana-
lyse local pathology. Recently the predictive value of DUS
in the detection of active synovitis and consequent ero-
sive progression has been assessed [31, 37, 38], demon-
strating the relevant role of Doppler modalities in disease
follow-up. The use of DUS in disease monitoring is there-
fore fundamental, sonography being more sensitive than
clinical assessment in the demonstration of active syno-
vitis [17, 18] and able to predict the onset of erosion [19].
Rheumatology key messages
. DUS is a valid and reliable tool for the assessment
of synovitis and enthesitis.
. No significant difference in sensitivity has been
found between colour and PD.
Disclosure statement: The authors have declared no con-
flicts of interest.
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